Immunohistochemistry has long been the gold-standard method for understanding the in situ expression patterns of therapeutically relevant proteins that are prognostic, predictive, or selective for patient management in targeted oncology. However, the detection of one or two proteins no longer provides enough information to draw effective conclusions for patient stratification and therapy guidance.
New demands placed on clinical tissue specimens, an emphasis on teasing more information from increasingly small biopsy material, have further spurred the development of multiplex IHC strategies.
This white paper from CellCarta describes the optimization and validation of a brightfield chromogenic triplex CD8/Granzyme B/FOXP3 immunohistochemistry assay and discusses how this assay could be used for future clinical applications to better predict response to therapy.
Offered Free by: CellCarta
See All Resources from: CellCarta
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.